Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids – including through non-invasive methods – and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.
Subscribe to see Profound Medical Corp.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Profound Medical Corp. is a medical devices company headquartered in Mississauga, Canada. It is publicly listed (PROF) with a market capitalisation of $207.3M. Xcout tracks 15 named people at Profound Medical Corp., including Arun Swarup Menawat (Chairman of the Board & Chief Executive Officer). Xcout recorded 3 job postings from Profound Medical Corp. in the last 90 days.
9 more named people on record for Profound Medical Corp., with roles, board committees and tenure — see the full roster →
Xcout recorded 3 job postings from Profound Medical Corp. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Profound Medical Corp.'s hiring signals →
A few of Profound Medical Corp.'s closest competitors — see the full list of competitors and alternatives →
Focal Medical develops and manufactures the Focal One HIFU Robotic System, a non-invasive medical device that utilizes high-intensity focused ultrasound technology to precisely target and ablate prostate tissue. The company serves urologists and healthcare facilities by providing equipment for prostate cancer management that preserves healthy surrounding tissue and minimizes side effects for patients.
Gynesonics, Inc. is a U.S. medical-device company that develops minimally invasive, incision-free treatments for uterine fibroids. Its Sonata System uses transcervical radiofrequency ablation with intrauterine ultrasound guidance and serves gynecologists and women seeking fibroid treatment.
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
IMRIS Inc. designs and manufactures innovative intraoperative MRI systems and surgical imaging solutions, including ceiling-mounted rail systems that bring diagnostic imaging directly to the patient during neurosurgery. The company also provides comprehensive operating suite design, installation, and clinical support services for healthcare facilities.
Focal Therapeutics provides the Focal One robotic system, which utilizes high-intensity focused ultrasound (HIFU) technology to non-invasively target and ablate prostate tissue for prostate cancer patients. The system is designed for urologists to precisely treat targeted lesions while sparing healthy surrounding tissue and minimizing side effects.
EDAP TMS S.A. operates as a holding company, with its subsidiary primarily focused on the innovation, manufacturing, and distribution of advanced, minimally invasive medical devices engineered to address urological conditions. The company's activities are organized into two principal divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS). The HIFU segment is dedicated to the creation, production, and commercialization of devices that employ HIFU technology for the precise, non-surgical elimination of certain localized tumors. In contrast, the UDS division concentrates on the entire lifecycle—from development and marketing to manufacturing and servicing—of medical instruments used for the minimally invasive diagnosis and treatment of various urological disorders, particularly urinary stones and other related clinical indications. This enterprise was founded on December 3, 1979, and its corporate headquarters are located in Vaulx-en-Velin, France.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.